Citation Tools

Original research
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

Download to a citation manager

Cite this article as:
de Jong LA, van der Velden AWG, Hulst MV, et al
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism